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Abstract
INTRODUCTION: Transient hypoxia and subsequent
reoxygenation are common phenomena in solid tumors
that greatly influence the outcome of radiation therapy.
This study was designed to determine how varying
cycles of hypoxia/reoxygenation affect the response
of cervical carcinoma cells irradiated under oxic and
hypoxic conditions and whether this could be mod-
ulated by proteasome inhibition. MATERIALS AND
METHODS: Plateau-phase SiHa cervical carcinoma
cells in culture were exposed to varying numbers of
30-minute cycles of hypoxia/reoxygenation directly
before irradiation under oxic or hypoxic conditions.
26S Proteasome activity was blocked by addition of
MG-132. Clonogenic survivalwasmeasuredbya colony-
forming assay. RESULTS: Under oxic conditions, re-
peated cycles of hypoxia/reoxygenation decreased the
clonogenic survival of SiHa cells. This effect was even
more pronounced after the inhibition of 26S proteasome
complex. In contrast, under hypoxic conditions, SiHa
cells were radioresistant, as expected, but this was in-
creased by proteasome inhibition. CONCLUSIONS: Pro-
teasome inhibition radiosensitizes oxygenated tumor
cells but may also protect tumor cells from ionizing
radiation under certain hypoxic conditions.
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Introduction
The basis of the curative effect of radiotherapy is DNA
damage in tumor cells. This cytotoxic effect of ionizing
radiation is modified by many factors, one of which is
oxygen. Hypoxic cells are two to three times more resistant
to ionizing irradiation [oxygen enhancement ratio (OER)]
than well-oxygenated cells [1]. The hypoxic cell fraction of a
tumor is, therefore, one of the most important factors deter-
mining the probability of local tumor control after radiation
treatment [2]. Hypoxia is frequently found in human tumors
and can be divided into chronic and acute hypoxia. Although
chronic hypoxia results from limited diffusion of oxygen from
capillaries to tumor cells, acute hypoxia occurs because of per-
fusion defects. Irregular tumor growth and the abnormal tumor
microenvironment cause existing blood vessels to open and
close because of microthrombosis or high intramural pressure.
This makes transient hypoxia and reoxygenation common
phenomena in tumors that have grown beyond a critical diame-
ter [3,4]. As a corollary, the oxygenation status of cells within
tumors undergoes frequent changes [5]. Changing oxygen
tensions cause the production of high levels of reactive oxygen
intermediate, which acts to select cells that can adapt to chang-
ing environmental conditions [6,7].
In the last few years, knowledge on the mechanisms of
adaptation to oxidative stress in mammalian cells has grown
[8,9]. The suggestion is that this results from the activation
of important signal transduction pathways that involve 26S
proteasome function [9,10], but little is known about the rele-
vance of these pathways to radiosensitivity (for a review, see
Adams et al. [11]).
26SProteasome is amulticatalytic ATP-dependent protease
complex that is responsible for the posttranslational control
of all short-lived and many long-lived proteins [12]. The activity
of this protease can be blocked by specific inhibitors such
as MG-132, lactacystein, or bortezomib [13,14]. Proteasome
inhibition effectively induces apoptosis and sensitizes cancer
cells to chemotherapy [15] and ionizing radiation [16,17].
Bortezomib (Velcade; formally known as PS-341), the first
specific proteasome inhibitor, has recently been approved by
the Food and Drug Administration to treat patients with mul-
tiple myeloma [18] and is presently on clinical trial for the
treatment of solid cancers and hematologic malignancies. The
mechanisms leading to induction of apoptosis and radio-
sensitization are currently not fully understood. Nevertheless,
knowledge on the effects of proteasome inhibitors on tumor
cells in different tumor microenvironments will possibly aid
decision making in situations where a combination of this new
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class of anticancer drugs and classic treatment modalities
might be thought beneficial.
In this study, we tested if the proteasome inhibitor MG-132
can be used to overcome the radioprotective effects of
acute hypoxia in a cervical cancer cell line. Although MG-
132 sensitized oxygenated cells to ionizing radiation, we
found that proteasome inhibition had no effect on acutely
hypoxic cells. In fact, proteasome inhibition protected hypoxic
cells that had undergone three cycles of hypoxia/reoxygena-
tion from ionizing radiation, indicating that pathophysiological
conditions might exist where proteasome inhibition may not
necessarily be cytotoxic to tumor cells.
Materials and Methods
Cell Culture
SiHa (ATCC,Manassas, VA) cervical carcinoma cells were
cultured in 75-cm2 flasks (BD Bioscience, San Jose, CA)
in Leibowitzs’ 15 medium (Gibco BRL, Gaithersburg, MD),
10%bovine serum (SeromedBiochromKG,Berlin,Germany),
MEM vitamins (Gibco BRL), 1% sodium pyruvate (Gibco
BRL; 100 mM), 1% penicillin/streptomycin (Sigma-Aldrich,
St. Louis, MO), and 0.5 mg/ml fungizone (amphotericin B;
Gibco BRL), and incubated in a humidified atmosphere at
37jC. Seventy-two hours before irradiation, cells were plated
at a density of 2.5  105 cells/cm2 in glass Petri dishes. Thirty
minutes before starting the first hypoxic cycle, MG-132 (Cal-
biochem, San Diego, CA) was added at a concentration of
50 mM. The inhibitor remained in the medium during periods
of preconditioning and radiation. Immediately after irradiation,
the medium was changed to wash out the inhibitor, and the
cells were incubated for an additional 4 hours to allow repair
before plating.
Hypoxic Conditions
A polyacrylic chamber was used to provide hypoxic con-
ditions. The chamber was placed into a 37jC shaking water
bath at low frequency. Prewarmed and moisturized gas
(nitrogen or air) was flushed into the chamber at a constant
flow rate of 1.5 l/min. To monitor the actual oxygen partial
pressure, an oxygen electrode (CellOx 325, Weilheim, Ger-
many) was placed into a medium-filled culture dish during all
experiments. Movement of the chamber in the shaking water
bath guaranteed a constant flow of medium around the
electrode, which is a precondition for exact measurements
of oxygen tension. After 20 minutes of flushing the chamber
with nitrogen, oxygen content in the medium remained
< 0.1%. pH values were also monitored and remained con-
stant. In reoxygenation experiments, each cycle of hypoxia
(30 minutes in total) was followed by a 30-minute incubation
interval, during which the chamber was flushed with air at a
flow rate of 1.5 l/min.
Irradiation
The cells were irradiated at the plateau phase of growth.
Irradiation was performed at room temperature using a linear
accelerator (Clinac; Varian, Palo Alto, CA). During transport
and irradiation, the chamber was flushed with a constant
nitrogen flow of 1.5 l/min to maintain hypoxic conditions, or
with air to maintain oxic conditions.
Colony-Forming Assay
Cells were trypsinized, counted, and diluted to a final
concentration of 106 cells/ml. Colony-forming assays were
performed by plating an appropriate number of cells into
culture dishes, in triplicate. After 14 days, cells were fixed
and stained with 1% crystal violet, and colonies containing
> 50 cellswere counted. The surviving fractionwas normalized
to the surviving fraction of the corresponding control, and
survival curves were fitted by a linear–quadratic model [19].
Dq and D0 were calculated from the survival curves using the
single-hit multitarget model of radiation dose survival. Dq is a
measure of the shoulder region of the curve and is where
the exponential region extrapolates to the x (dose) axis,
whereas D0 represents the slope of the exponential region.
Results
The clonogenic survival of SiHa cells treated with radiation
doses of 0, 2, 4, 6, and 8 Gy under oxic and hypoxic con-
ditions is shown in Figure 1. As expected, under hypoxic
conditions, clonogenic survival increased with an OER of 2.9
(OER measured at D0 values). Under oxic conditions, inhibi-
tion of proteasome function by MG-132 (50 mM) for 3 hours
before irradiation sensitized SiHa cells. The increase in
radiosensitivity was 1.6-fold (± 0.2 for LD10;P < .05, Student’s
t test). Three cycles of hypoxia/reoxygenation, followed
by irradiation under oxic conditions, also resulted in radio-
sensitization (1.35 ± 0.24–fold for LD10) that was not further
enhanced by proteasome inhibition (1.75 ± 0.19–fold for
LD10, not significant) with hypoxia/reoxygenation alone
Figure 1. Clonogenic survival of SiHa cervical carcinoma cells in the plateau
phase, irradiated under oxic (o) and hypoxic (4) conditions. Data from three
independent experiments, each performed in triplicate (mean ± SEM).
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(Figure 2). Under oxic conditions, none of the treatments
significantly changed plating efficacy (PE; Table 1).
Interestingly, one or three cycles of hypoxia/reoxygenation
did not affect intrinsic radiosensitivity under hypoxic condi-
tions (Figure 3). Only after 15 cycles were cells sensitized
to irradiation (Figure 3) (1.38 ± 0.06–fold for LD10; P < .05,
Student’s t test).
Cells that had been preconditioned with three cycles of
hypoxia/reoxygenation and had been treated with MG-132
(50 mM) for 3 hours were remarkably radioresistant under
hypoxic conditions (1.75 ± 0.06–fold;P < .05, Student’s t test),
as measured by LD50 values, although addition of MG-132
alone did not significantly change clonogenic survival under
such conditions (Figure 4). The observed effect was less
pronounced for LD10 values, increased the survival curve’s
shoulder, and caused a 5.3-fold increase in Dq (Table 1).
Although treatment of SiHa cells with either MG-132
alone, one cycle of hypoxia/reoxygenation, or three cycles
of hypoxia/reoxygenation did not alter PE under hypoxic
conditions, the combination of MG-132 treatment and cyclic
reoxygenation, as well as 15 cycles of reoxygenation, signifi-
cantly decreased PE to 33.1 ± 1.8% (P < .05, Student’s t test)
and 28.1 ± 1.1% (P < .05, Student’s t test), respectively.
Discussion
The hypoxic fraction of cells in a tumor, in particular acute
hypoxia resulting from fluctuations in blood supply, is one of
the most important factors determining the curability of can-
cer by radiation therapy [2]. In contrary to in vitro conditions,
the oxygenation status of tumor cells in vivo is characterized
Figure 2. Clonogenic survival of SiHa cervical carcinoma cells in the plateau
phase, irradiated under oxic conditions. Data from three independent experi-
ments, each performed in triplicate (mean ± SEM). MG-132 was added
30 minutes before the start of the first cycle of hypoxia and remained in
the medium until cells were irradiated. Control cells (o), three cycles of
hypoxia/reoxygenation (w), MG-132 at 50 M (4), three cycles of hypoxia/
reoxygenation, and preincubation with MG-132 at 50 M (5).
Table 1. Radiobiologic Parameters of SiHa Cervical Cancer Cells (mean ± SEM).
Treatment PE (%) D0 (Gy) Dq (Gy) n LD50 (Gy) Dose Enhancement
Ratio
LD10 (Gy) Dose Enhancement
Ratio
Oxic Control 50.6 ± 3.8 1.91 [0.16] 2.46 [1.0] 7.92 2.48 ± 0.48 – 5.26 ± 0.38 –
MG-132 38.1 ± 5.4 0.75 [0.39] 1.51 [3.7] 7.57 1.26 ± 0.25* 1.96 ± 0.54 3.23 ± 0.32* 1.63 ± 0.2
3 Reoxygenation 47.6 ± 4.2 0.9 [0.16] 2.05 [1.1] 11.18 1.63 ± 0.6 1.52 ± 0.64 3.9 ± 0.63 1.35 ± 0.24
3 Reoxygenation MG-132 42.4 ± 6.4 0.7 [0.37] 1.44 [3.5] 7.95 1.16 ± 0.18* 2.14 ± 0.53 3.01 ± 0.24* 1.75 ± 0.19
Hypoxia Control 44.8 ± 2.1 3.41 [0.98] 0.81 [1.9] 1.27 2.97 ± 0.11 – 8.5 ± 0.13 –
MG-132 41.7 ± 3.5 3.05 [1.14] 1.84 [4.9] 1.82 3.62 ± 0.44 0.82 ± 0.10 8.46 ± 0.36 1.00 ± 0.05
3 Reoxygenation 44.3 ± 10 3.63 [1.6] 0.0 [3.7] 1 2.52 ± 0.33 1.17 ± 0.15 8.4 ± 0.46 1.02 ± 0.06
3 Reoxygenation MG-132 33.1 ± 1.8* 2.46 [0.85] 4.29 [1.1] 5.74 5.2 ± 0.16* 0.57 ± 0.03 9.47 ± 0.19* 0.9 ± 0.02
1 Reoxygenation 47.2 ± 1.9 3.27 [1.3] 1.56 [1.9] 1.6 3.64 ± 0.13* 0.86 ± 0.1 8.6 ± 0.20 0.99 ± 0.03
15 Reoxygenation 28.1 ± 1.1* 1.96 [0.42] 1.63 [1.0] 2.3 2.45 ± 0.31 1.12 ± 0.09 6.1 ± 0.23* 1.38 ± 0.06
Ninety-five percent confidence intervals are presented in square brackets.
*P < .05.
Figure 3. Clonogenic survival of SiHa cervical carcinoma cells in the plateau
phase, irradiated under hypoxic conditions. Cells were preconditioned with 0
(o), 1 (4), 3 (w), or 15 (5) cycles of hypoxia/reoxygenation. Data from three
independent experiments, each performed in triplicate (mean ± SEM).
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by frequent fluctuations between oxic and hypoxic conditions
[5]. Recent reports demonstrated not only that hypoxia
selects for cells defective in apoptotic pathways [6] but also
that survival-related signal transduction pathways involving
NF-nB, AP-1, and HIF-1 that are switched on during the
hypoxic response might make cells more resistant to radia-
tion therapy [20–22]. Because many of these pathways are
tightly controlled by the 26S proteasome, we became inter-
ested on whether specific inhibitors of this multicatalytic
protease, which is being targeted in clinical cancer trials
[18], would alter the response of cervical cancer cells ex-
posed to rapidly changing oxygen tensions when irradiated
under oxic and hypoxic conditions. To investigate the radia-
tion response of cells under changing oxygen tensions, we
designed an experimental setting that allowed controlled and
reproducible changes between hypoxia and reoxygenation.
Responses were studied in plateau-phase cells because it
has been previously suggested that plateau-phase cells
could be a better in vitromodel for tumors than exponentially
growing cultures [23] because they are likely to repair DNA
damage better, which would contribute to the radioresistance
of tumors in vivo [24].
Using SiHa cervical cancer cells, we found an OER of 2.9
for acute hypoxic cells when compared to control cells under
oxic conditions. This value compared well to published OERs
[1] and verified that low oxygen tensions were reached in our
experimental setting, as measured by the oxygen electrode
placed on a control Petri dish.
Exposure of the cells to three cycles of hypoxia/reoxygen-
ation sensitized the cells to ionizing radiation under oxic
conditions as did pretreatment with the proteasome inhibitor
MG-132.Wehave previously shown that this treatment inhibits
proteasome function almost completely and radiosensitizes
HD-MyZ cancer cells; thus, the latter was expected [16].
However, the combined treatment of proteasome inhibition
and cyclic exposure to hypoxia and reoxygenation was not
additive, indicating that both effects may have overlapping
mechanisms. Nevertheless, our findings indicate that treat-
ment with proteasome inhibitors will not negatively affect the
radiation response of oxygenated and reoxygenated cells
under oxic conditions and, if anything, will radiosensitize them.
The outcome was very different under hypoxic conditions.
Pretreatment with either one or three cycles of hypoxia/
reoxygenation did not cause any significant change in radia-
tion response. Only after 15 cycles of hypoxia/reoxygenation
were cells sensitized (1.38-fold) to radiation, with a 28.1%
reduction in overall PE. This decrease in PE is in accordance
with previous studies showing that cycles of hypoxia/re-
oxygenation induced apoptosis in a portion of cells, thereby
selecting for cells with diminished apoptotic potential [6,25]. It
was surprising to see that the proteasome inhibitor MG-132
was unable to sensitize hypoxic cells to ionizing radiation.
Furthermore, in cells pretreated with three cycles of hypoxia/
reoxygenation, there was a substantial increase of the
shoulder portion of the survival curve. Therefore, cells were
protected from radiation especially at lower doses, such as
those given clinically (around 2 Gy). The lack of a sensitizing
effect of proteasome inhibition under hypoxic conditions
might be related to the fact that at least part of the toxicity
of proteasome inhibition in tumor cells relates to the gener-
ation of endoplasmic reticulum stress–reactive oxygen spe-
cies (ROS) [26], which are, in general, known to be reduced
under hypoxic conditions, and that the 26S proteasome is
redox-sensitive itself [27–29]. So far, the process of DNA
repair by nonhomologous end joining, the major repair mech-
anism for radiation-induced DNA double-strand breaks, has
not been directly linked to proteasome function. However,
there is increasing evidence that it may be [30], as are
nucleotide excision repair [31], base excision repair, and
homologous recombination [30]. Although these reports
may explain the radiosensitizing effects of MG-132 under
oxic conditions, they failed to explain the radioprotective
properties of proteasome inhibition after cyclic reoxygenation
when cells were irradiated under hypoxic conditions.
Taken together, one may speculate that proteasome inhi-
bition acts in two different ways: on one hand, it activates the
cellular death program and sensitizes to cytotoxic treatment
by a ROS-dependent pathway; on the other hand, protea-
some inhibition causes a cellular stress response that counter-
balances its own cytotoxic effects. In the absence of oxygen
and in the presence of additional stressors such as hypoxia/
reoxygenation, cytotoxic effects might be outbalanced and
proteasome inhibition could even lead to cytoprotection.
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